ArticlePharmacoEconomics - open2025

Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment.

Yan Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.